Resources - COVID-19 information
Section dedicated to information on pharmacovigilance of medicinal products used to treat and prevent COVID-19 (coronavirus).
The section is divided into two parts: one part relating to links to national and international institutional websites on SARS-CoV-2 (COVID-19) and another part relating to research documents by the North American chapter (NASoP) and the Italian Society of Pharmacology (SIF).
This page will be regularly updated.
Here you will find some links to national and international institutional websites and published papers on COVID-19. Stay informed with the latest clinical research and resources.
World Health Organisation
Centers for Disease Control and Prevention
CUS National Institute of Health about the COVID-19 therapeutic options under investigation
European Medicines Agency
COVID-19 data sources (Knowledge Portal on Innovation and Access to Medicines)
The New England Journal Of Medicine
Oxford Covid-19 Evidence service
The Royal College of Obstetricians and Gynaecologists (RCOG)
Italian Society of Pharmacology - English COVID-19 section
International Union of Pharmacology and Clinical Pharmacology (IUPHAR)
NIPH-Live map of COVID-19 evidence
Position Papers and initiatives
ISoP colleagues in the North American Chapter of ISoP (NASoP) and the Italian Society of Pharmacology (SIF) are working on proposals to monitor the safety of medicines and vaccines to treat and prevent COVID-19.
Official statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary
Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary
Simplified description of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Viral lifecycle and drug repurposing strategies
The contents of this page are intended for purely informational purposes (the list is not exhaustive).